Table 2.
Incidence and multiplicity of colonic lesions in the mice in each group.
| Group no. | Treatment (no. of mice examined) | Mucosal ulcer | High-grade dysplasia |
|---|---|---|---|
| 1 | ABAQ a (100 mg/kg bw) → 2% DSS (15) | 10/15 (67%) 1.40 ± 1.18 b | 4/15 (27%) c,d 0.53 ± 1.13 |
| 2 | ABAQ (200 mg/kg bw) → 2% DSS (15) | 11/15 (73%) 1.27 ± 1.16 | 10/15 (67%) e 1.60 ± 1.50 |
| 3 | ABAQ (200 mg/kg bw) (5) | 0/5 (0%) 0 | 1/5 (20%) 0.20 ± 0.45 |
| 4 | Solvent → 2% DSS (5) | 5/5 (100%) 1.80 ± 0.84 f | 0/5 (0%) 0 |
| 5 | None (8) | 0/8 (0%) 0 | 0/8 (0%) 0 |
a
ABAQ, 5-amino-6-hydroxy-8H-benzo[6,7]azepino[5,4,3-de]quinolin-7-one; DSS, dextran sodium sulfate.
b
Mean ± SD.
c,d,e Significantly different from group 2 (cp < 0.05), group 3 (dp < 0.05) and group 4 (ep < 0.05) according to the Fisher's exact probability test.
f
Significantly different from group 5 (p < 0.05) according to a one-way ANOVA and the Tukey–Kramer Multiple Comparison test.